Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Incannex Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IHL is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IHL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
7 Day Return
1 Year Return
Return vs Industry: IHL exceeded the Australian Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: IHL exceeded the Australian Market which returned 37.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Incannex Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StIncannex Healthcare (ASX:IHL) Has Rewarded Shareholders With An Exceptional 774% Total Return On Their Investment
5 months ago | Simply Wall StHow Is Incannex Healthcare's (ASX:IHL) CEO Compensated?
10 months ago | Simply Wall StHere's Why We're Not Too Worried About Impression Healthcare's (ASX:IHL) Cash Burn Situation
Is Incannex Healthcare undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IHL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IHL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IHL is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: IHL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IHL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IHL is overvalued based on its PB Ratio (26.9x) compared to the AU Pharmaceuticals industry average (3.3x).
How is Incannex Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Incannex Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Incannex Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IHL is currently unprofitable.
Growing Profit Margin: IHL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IHL is unprofitable, but has reduced losses over the past 5 years at a rate of 38% per year.
Accelerating Growth: Unable to compare IHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).
Return on Equity
High ROE: IHL has a negative Return on Equity (-41.46%), as it is currently unprofitable.
How is Incannex Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: IHL's short term assets (A$12.2M) exceed its short term liabilities (A$378.4K).
Long Term Liabilities: IHL has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IHL is debt free.
Reducing Debt: IHL had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IHL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IHL has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 21% each year.
What is Incannex Healthcare current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IHL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IHL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IHL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IHL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Joel Bradley Latham has been Chief Executive Officer at Incannex Healthcare Limited (also known as Impression Healthcare Ltd.) since June 29, 2018 and has been its Managing Director and Executive Direc...
CEO Compensation Analysis
Compensation vs Market: Joel's total compensation ($USD303.47K) is below average for companies of similar size in the Australian market ($USD496.94K).
Compensation vs Earnings: Joel's compensation has increased whilst the company is unprofitable.
Experienced Management: IHL's management team is considered experienced (2.9 years average tenure).
Experienced Board: IHL's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.1%.
Incannex Healthcare Limited's company bio, employee growth, exchange listings and data sources
- Name: Incannex Healthcare Limited
- Ticker: IHL
- Exchange: ASX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$322.839m
- Shares outstanding: 1.06b
- Website: https://www.incannex.com.au
- Incannex Healthcare Limited
- Rialto South Tower
- Level 39
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name....
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 08:24|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.